Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980371 | 1.00 | CHRM3 (0.57) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL827869 | 1.00 | CHRM3 (0.57) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL7206193 | 1.00 | CHRM3 (0.57) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Chloromethane SCHEMBL27725461 | 0.97 | CHRM3 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL9148888 | 0.92 | CHRM3 (0.50) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL7648970 | 0.88 | CHRM3 (0.48) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL10813827 | 0.88 | CHRM3 (0.45) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL7525984 | 0.86 | CHRM3 (0.45) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL10813833 | 0.82 | CHRM3 (0.42) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL5857109 | 0.77 | CHRM3 (0.38) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050226-A1 | Dopamine analog amide | SHASHOUA VICTOR E (US) | 2003-03-13 | — | — | US | disclosed |
| US-6407137-B2 | A PRODRUG COMPOUND CAPABLE OF FACILITATING THE PASSAGE OF A DRUG ACROSS THE BLOOD BRAIN BARRIER COMPRISING A FATTY ACID COUPLED TO A DRUG TO FORM A PRODRUG | PROTARGA, INC. | 2002-06-18 | — | — | US | disclosed |
| US-20010056116-A1 | Dopamine analog amide | LUITPOLD PHARMACEUTICALS, INC. | 2001-12-27 | — | — | US | disclosed |
| US-6258836-B1 | FATTY ACID COUPLED TO ANTIAIDS SUBSTANCE, ANTIBIOTIC, CHOLINERGIC AGONIST AND OTHER USES FOR PASSING THE BLOOD BRAIN BARRIER | PROTARGA, INC. | 2001-07-10 | — | — | US | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5994392-A | PASSAGE OF DRUG THROUGH BLOOD BRAIN BARRIER | NEUROMEDICA, INC. (US) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056116-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | CHRM3 999/4885CHRM2 1324/4885CHRM1 995/4885 |
| US-20030050226-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | CHRM3 999/4885CHRM2 1324/4885CHRM1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.